Valérie Deckert

Valérie Deckert

Auto-generated profile, based on publicly available information

Valérie Deckert

Univ. Bourgogne Franche-Comté, INSERM, LNC UMR1231, LabEX LipSTIC, F-21000 Dijon, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
ADAloïs Dusuel
Aloïs Dusuel
VDValérie Deckert
Valérie Deckert
JBJean-Paul Pais de Barros
Jean-Paul Pais de Barros
KDKevin van Dongen
Kevin van Dongen
HCHélène Choubley
Hélène Choubley
TGThomas GAUTIER
Thomas GAUTIER
Aloïs Dusuel, Valérie Deckert, Jean-Paul PAIS DE BARROS, Kevin Van Dongen, Hélène Choubley, Emilie Charron, Naig Le Guern, Jérôme Labbé, Stéphane Mandard, Jacques Grober, Laurent Lagrost, Thomas Gautier

10 February 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CCCécile Chagué
Cécile Chagué
TGThomas GAUTIER
Thomas GAUTIER
LZLudivine Dal Zuffo
Ludivine Dal Zuffo
JBJean-Paul Pais de Barros
Jean-Paul Pais de Barros
AWAudrey Wetzel
Audrey Wetzel
PSPhilippe Saas
Philippe Saas
Acute graft-versus-host disease (aGVHD) is a major limitation of the therapeutic potential of allogeneic hematopoietic cell transplantation. Lipopolysaccharides (LPS) derived from intestinal Gram-negative bacteria are well-known aGVHD triggers and amplifiers. Here, we explored the LPS metabolism in aGVHD mouse models using an innovative quantification method. We demonstrated that systemic LPS accumulation after transplantation was due, at least partly, to a defect in its clearance through lipoprotein-mediated transport to the liver (i.e., the so-called reverse LPS transport). After transplantation, reduced circulating HDL concentration impaired LPS neutralization and elimination through biliary flux. Accordingly, HDL-deficient (Apoa1tm1Unc) recipient mice developed exacerbated aGVHD. Repeated administration of HDL isolated from human plasma significantly decreased the mortality and the severity of aGVHD. While the potential role of HDL in scavenging circulating LPS was examined in this study, it appears that HDL plays a more direct immunomodulatory role by limiting or controlling aGVHD. Notably, HDL infusion mitigated liver aGVHD by diminishing immune infiltration (e.g., interferon-γ-secreting CD8+ T cells and non-resident macrophages), systemic and local inflammation (notably cholangitis). Hence, our results revealed the interest of HDL-based therapies in the prevention of aGVHD.